Losatuxizumab

Cat. No.:	HY-P99715
CAS No.:	1801544-27-3
Target:	EGFR
Pathway:	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description

Losatuxizumab (ABT-806) is an anti-EGFR monoclonal antibody. Losatuxizumab binds to EGFR with EC_{50}s of 0.96 nM for EGFR wild-type, 0.09 nM for $EGFR^{C271A,C283A}$, 0.12 nM for EGFRvIII, 0.66 nM for EGFR1-501. Losatuxizumab can be used for research of EGFR-expressing cancers[1][2].

In Vitro

Losatuxizumab (0.001 nM-100 nM) binds to EGFRvIII-expressing cell line U87MGde2-7[1].
Losatuxizumab inhibits EGF-mediated EGFR phosphorylation in a NR6 $huEGFR^{C271A,C283A}$ cell line, with an IC_{50} of 1.2 nM[2].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Lorigerlimab has antitumor activities in various wild-type EGFR-expressing squamous cell carcinoma xenograft model[1].
Lorigerlimab (40 mg/kg, i.p.) significantly inhibits growth of U87MGde2-7 tumor in mice[1].
Lorigerlimab (10 and 40 mg/kg, i.p.) prolongs survival and reduces levels of pEGFR in PDX GBM model (SN0207 tumor)[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	PDX GBM model (SN0207 tumor)[1]
Dosage:	40 mg/kg
Administration:	i.p.
Result:	Prolonged survival rate, and reduced levels of pEGFR in tumor.

REFERENCES

[1]. Reilly EB, et al. Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody. Mol Cancer Ther. 2015 May;14(5):1141-51.

[2]. Phillips AC, et al. ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope. Mol Cancer Ther. 2016 Apr;15(4):661-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA